TWST
Overvalued by 10.1% based on the discounted cash flow analysis.
Market cap | $2.71 Billion |
---|---|
Enterprise Value | $2.41 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-3.35 |
Beta | 3.34 |
Outstanding Shares | 58,225,999 |
Avg 30 Day Volume | 1,322,021 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -14.09 |
---|---|
PEG | 61.01 |
Price to Sales | 11.75 |
Price to Book Ratio | 5.22 |
Enterprise Value to Revenue | 8.7 |
Enterprise Value to EBIT | -12.63 |
Enterprise Value to Net Income | -13 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary techno...